Therapy escape mechanisms in the malignant prostate

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages 133-144

  Santer, Frédéric R ^a   Erb, Holger H H ^b   McNeill, Rhiannon V ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

AR targeting therapies; Bypass signalling; Cancer stem cells; Histologic transformation; Target modification; Therapy resistance mechanisms

Indexed keywords

ANDROGEN RECEPTOR; DENDRITIC CELL VACCINE; GLUCOCORTICOID RECEPTOR; TAXANE DERIVATIVE;

ANDROGEN DEPRIVATION THERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL TRANSDIFFERENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTERNAL BEAM RADIOTHERAPY; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HYPERSENSITIVITY; MOLECULAR MODEL; MUTATIONAL ANALYSIS; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; TRANSACTIVATION; TUMOR ESCAPE; ANIMAL; CELL TRANSFORMATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIATION TOLERANCE;

ANIMALS; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIATION TOLERANCE; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84948712974     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.08.005     Document Type: Review

References (177)

1. McNeal J.E. Normal and pathologic anatomy of prostate. Urology 1981, 17:11-16.
2. Isaacs J.T. Prostate stem cells and benign prostatic hyperplasia. Prostate 2008, 68:1025-1034. 10.1002/pros.20763.
3. Krijnen J.L., Janssen P.J., Ruizeveld de Winter J.A., van Krimpen H., Schröder F.H., van der Kwast T.H. Do neuroendocrine cells in human prostate cancer express androgen receptor?. Histochemistry 1993, 100:393-398.
4. Lilja H., Abrahamsson P.A. Three predominant proteins secreted by the human prostate gland. Prostate 1988, 12:29-38.
5. Lang S.H., Stark M., Collins A., Paul A.B., Stower M.J., Maitland N.J. Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth Differ. 2001, 12:631-640.
6. Rumpold H., Heinrich E., Untergasser G., Hermann M., Pfister G., Plas E., et al. Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 2002, 53:101-108. 10.1002/pros.10129.
7. Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 2014, 65:467-479. 10.1016/j.eururo.2013.11.002.
8. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 1972, 22:232-240.
9. Scher H.I., Fizazi K., Saad F., Taplin M.-E., Sternberg C.N., Miller K., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 2012, 367:1187-1197. 10.1056/NEJMoa1207506.
10. Fizazi K., Scher H.I., Molina A., Logothetis C.J., Chi K.N., Jones R.J., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012, 13:983-992. 10.1016/S1470-2045(12)70379-0.
11. Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 2014, 371:424-433. 10.1056/NEJMoa1405095.
12. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790. 10.1126/science.1168175.
13. Lubahn D.B., Brown T.R., Simental J.A., Higgs H.N., Migeon C.J., Wilson E.M., et al. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:9534-9538.
14. Jenster G., van der Korput H.A.G.M., van Vroonhoven C., van der Kwast T.H., Trapman J., Brinkmann A.O. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. 1991, 5:1396-1404. 10.1210/mend-5-10-1396.
15. Culig Z., Santer F.R. Androgen receptor co-activators in the regulation of cellular events in prostate cancer. World J. Urol. 2012, 30:297-302. 10.1007/s00345-011-0797-6.
16. Lovly C.M., Shaw A.T. Molecular pathways: Resistance to kinase inhibitors and implications for therapeutic strategies. Clin. Cancer Res. 2014, 20:2249-2256. 10.1158/1078-0432.CCR-13-1610.
17. Linja M.J., Savinainen K.J., Saramäki O.R., Tammela T.L., Vessella R.L., Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61:3550-3555.
18. Ford O.H., Gregory C.W., Kim D., Smitherman A.B., Mohler J.L. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J. Urol. 2003, 170:1817-1821. 10.1097/01.ju.0000091873.09677.f4.
19. Qu X., Randhawa G., Friedman C., Kurland B.F., Glaskova L., Coleman I., et al. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS ONE 2013, 8:e74671. 10.1371/journal.pone.0074671.
20. Waltering K.K., Helenius M.A., Sahu B., Manni V., Linja M.J., Jänne O.A., et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 2009, 69:8141-8149. 10.1158/0008-5472.CAN-09-0919.
21. Urbanucci A., Sahu B., Seppälä J., Larjo A., Latonen L.M., Waltering K.K., et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 2012, 31:2153-2163. 10.1038/onc.2011.401.
22. Merson S., Yang Z.H., Brewer D., Olmos D., Eichholz A., McCarthy F., et al. Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer. Br. J. Cancer 2014, 110:1655-1662. 10.1038/bjc.2014.13.
23. Palmberg C., Koivisto P., Kakkola L., Tammela T.L., Kallioniemi O.P., Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J. Urol. 2000, 164:1992-1995.
24. Shaffer D.R., Leversha M.A., Danila D.C., Lin O., Gonzalez-Espinoza R., Gu B., et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res. 2007, 13:2023-2029. 10.1158/1078-0432.CCR-06-2701.
25. Geng C., Rajapakshe K., Shah S.S., Shou J., Eedunuri V.K., Foley C., et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014, 74:5631-5643. 10.1158/0008-5472.CAN-14-0476.
26. An J., Wang C., Deng Y., Yu L., Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014, 6:657-669. 10.1016/j.celrep.2014.01.013.
27. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.-P., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44:685-689. 10.1038/ng.2279.
28. Grasso C.S., Wu Y.-M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243. 10.1038/nature11125.
29. Qi J., Tripathi M., Mishra R., Sahgal N., Fazli L., Fazil L., et al. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell 2013, 23:332-346. 10.1016/j.ccr.2013.02.016.
30. Köhler A., Demir U., Kickstein E., Krauss S., Aigner J., Aranda-Orgillés B., et al. A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling. Mol. Cancer 2014, 13:146. 10.1186/1476-4598-13-146.
31. Quarmby V.E., Yarbrough W.G., Lubahn D.B., French F.S., Wilson E.M. Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol. Endocrinol. 1990, 4:22-28. 10.1210/mend-4-1-22.
32. Cai C., He H.H., Chen S., Coleman I., Wang H., Fang Z., et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011, 20:457-471. 10.1016/j.ccr.2011.09.001.
33. McDonald S., Brive L., Agus D.B., Scher H.I., Ely K.R. Ligand responsiveness in human prostate cancer: Structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res. 2000, 60:2317-2322.
34. Azad A.A., Volik S.V., Wyatt A.W., Haegert A., Le Bihan S., Bell R.H., et al. Androgen receptor gene aberrations in circulating cell-free DNA: Biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res. 2015, 10.1158/1078-0432.CCR-14-2666.
35. Joseph J.D., Lu N., Qian J., Sensintaffar J., Shao G., Brigham D., et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013, 3:1020-1029. 10.1158/2159-8290.CD-13-0226.
36. Korpal M., Korn J.M., Gao X., Rakiec D.P., Ruddy D.A., Doshi S., et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013, 3:1030-1043. 10.1158/2159-8290.CD-13-0142.
37. Chen E.J., Sowalsky A.G., Gao S., Cai C., Voznesensky O., Schaefer R., et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin. Cancer Res. 2015, 21:1273-1280. 10.1158/1078-0432.CCR-14-1220.
38. Yoshida T., Kinoshita H., Segawa T., Nakamura E., Inoue T., Shimizu Y., et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res. 2005, 65:9611-9616. 10.1158/0008-5472.CAN-05-0817.
39. Culig Z., Hobisch A., Cronauer M.V., Cato A.C., Hittmair A., Radmayr C., et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 1993, 7:1541-1550. 10.1210/mend.7.12.8145761.
40. Tan J., Sharief Y., Hamil K.G., Gregory C.W., Zang D.-Y., Sar M., et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 1997, 11:450-459. 10.1210/mend.11.4.9906.
41. Taplin M.E., Bubley G.J., Ko Y.J., Small E.J., Upton M., Rajeshkumar B., et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999, 59:2511-2515.
42. Zhao X.Y., Malloy P.J., Krishnan A.V., Swami S., Navone N.M., Peehl D.M., et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 2000, 6:703-706. 10.1038/76287.
43. Culig Z., Stober J., Gast A., Peterziel H., Hobisch A., Radmayr C., et al. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect. Prev. 1996, 20:68-75.
44. Rodriguez-Vida A., Bianchini D., Van Hemelrijck M., Hughes S., Malik Z., Powles T., et al. Is there an antiandrogen withdrawal syndrome with enzalutamide?. BJU Int. 2015, 115:373-380. 10.1111/bju.12826.
45. Nieh P.T. Withdrawal phenomenon with the antiandrogen casodex. J. Urol. 1995, 153:1070-1072. (discussion 1072-1073).
46. Scher H.I., Kelly W.K. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 1993, 11:1566-1572.
47. Ni L., Llewellyn R., Kesler C.T., Kelley J.B., Spencer A., Snow C.J., et al. Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor. Mol. Cell. Biol. 2013, 33:4766-4778. 10.1128/MCB.00647-13.
48. Duff J., McEwan I.J. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Mol. Endocrinol. 2005, 19:2943-2954. 10.1210/me.2005-0231.
49. Libertini S.J., Tepper C.G., Rodriguez V., Asmuth D.M., Kung H.-J., Mudryj M. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res. 2007, 67:9001-9005. 10.1158/0008-5472.CAN-07-1072.
50. Li Y., Hwang T.H., Oseth L.A., Hauge A., Vessella R.L., Schmechel S.C., et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 2012, 31:4759-4767. 10.1038/onc.2011.637.
51. Nyquist M.D., Li Y., Hwang T.H., Manlove L.S., Vessella R.L., Silverstein K.A.T., et al. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:17492-17497. 10.1073/pnas.1308587110.
52. Liu L.L., Xie N., Sun S., Plymate S., Mostaghel E., Dong X. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 2014, 33:3140-3150. 10.1038/onc.2013.284.
53. Lu J., Van der Steen T., Tindall D.J. Are androgen receptor variants a substitute for the full-length receptor?. Nat. Rev. Urol. 2015, 12:137-144. 10.1038/nrurol.2015.13.
54. Streicher W., Zengerling F., Laschak M., Weidemann W., Höpfner M., Schrader A.J., et al. AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells. World J. Urol. 2012, 30:333-339. 10.1007/s00345-012-0842-0.
55. Chan S.C., Li Y., Dehm S.M. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J. Biol. Chem. 2012, 287:19736-19749. 10.1074/jbc.M112.352930.
56. Mostaghel E.A., Marck B.T., Plymate S.R., Vessella R.L., Balk S., Matsumoto A.M., et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 2011, 17:5913-5925. 10.1158/1078-0432.CCR-11-0728.
57. Li Y., Chan S.C., Brand L.J., Hwang T.H., Silverstein K.A.T., Dehm S.M. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013, 73:483-489. 10.1158/0008-5472.CAN-12-3630.
58. Hu R., Dunn T.A., Wei S., Isharwal S., Veltri R.W., Humphreys E., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009, 69:16-22. 10.1158/0008-5472.CAN-08-2764.
59. Qu Y., Dai B., Ye D., Kong Y., Chang K., Jia Z., et al. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci. Rep. 2015, 5:7654. 10.1038/srep07654.
60. Yu Z., Chen S., Sowalsky A.G., Voznesensky O.S., Mostaghel E.A., Nelson P.S., et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin. Cancer Res. 2014, 20:1590-1600. 10.1158/1078-0432.CCR-13-1863.
61. Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014, 371:1028-1038. 10.1056/NEJMoa1315815.
62. Hu R., Lu C., Mostaghel E.A., Yegnasubramanian S., Gurel M., Tannahill C., et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012, 72:3457-3462. 10.1158/0008-5472.CAN-11-3892.
63. Hobisch A., Eder I.E., Putz T., Horninger W., Bartsch G., Klocker H., et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998, 58:4640-4645.
64. Yang L., Wang L., Lin H.-K., Kan P.-Y., Xie S., Tsai M.-Y., et al. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem. Biophys. Res. Commun. 2003, 305:462-469.
65. Ueda T., Bruchovsky N., Sadar M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 2002, 277:7076-7085. 10.1074/jbc.M108255200.
66. Ueda T., Mawji N.R., Bruchovsky N., Sadar M.D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem. 2002, 277:38087-38094. 10.1074/jbc.M203313200.
67. Rocha J., Zouanat F.Z., Zoubeidi A., Hamel L., Benidir T., Scarlata E., et al. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. Mol. Cell. Endocrinol. 2013, 381:140-149. 10.1016/j.mce.2013.07.017.
68. Malinowska K., Neuwirt H., Cavarretta I.T., Bektic J., Steiner H., Dietrich H., et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr. Relat. Cancer 2009, 16:155-169. 10.1677/ERC-08-0174.
69. Guo Z., Dai B., Jiang T., Xu K., Xie Y., Kim O., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006, 10:309-319. 10.1016/j.ccr.2006.08.021.
70. Summy J.M., Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003, 22:337-358.
71. Desai S.J., Ma A.-H., Tepper C.G., Chen H.-W., Kung H.-J. Inappropriate activation of the androgen receptor by nonsteroids: Involvement of the Src kinase pathway and its therapeutic implications. Cancer Res. 2006, 66:10449-10459. 10.1158/0008-5472.CAN-06-2582.
72. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994, 54:5474-5478.
73. Heemers H.V., Regan K.M., Schmidt L.J., Anderson S.K., Ballman K.V., Tindall D.J. Androgen modulation of coregulator expression in prostate cancer cells. Mol. Endocrinol. 2009, 23:572-583. 10.1210/me.2008-0363.
74. Heemers H.V., Sebo T.J., Debes J.D., Regan K.M., Raclaw K.A., Murphy L.M., et al. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res. 2007, 67:3422-3430. 10.1158/0008-5472.CAN-06-2836.
75. Debes J.D., Schmidt L.J., Huang H., Tindall D.J. p300 Mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res. 2002, 62:5632-5636.
76. Gong J., Zhu J., Goodman O.B., Pestell R.G., Schlegel P.N., Nanus D.M., et al. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 2006, 25:2011-2021. 10.1038/sj.onc.1209231.
77. Comuzzi B., Nemes C., Schmidt S., Jasarevic Z., Lodde M., Pycha A., et al. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J. Pathol. 2004, 204:159-166. 10.1002/path.1609.
78. Merkle D., Hoffmann R. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor. Cell. Signal. 2011, 23:507-515. 10.1016/j.cellsig.2010.08.017.
79. Kim J., Jia L., Stallcup M.R., Coetzee G.A. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus. J. Mol. Endocrinol. 2005, 34:107-118. 10.1677/jme.1.01701.
80. Choi H.-K., Yoo J.-Y., Jeong M.-H., Park S.-Y., Shin D.-M., Jang S.-W., et al. Protein kinase A phosphorylates NCoR to enhance its nuclear translocation and repressive function in human prostate cancer cells. J. Cell. Physiol. 2013, 228:1159-1165. 10.1002/jcp.24269.
81. Laschak M., Bechtel M., Spindler K.-D., Hessenauer A. Inability of NCoR/SMRT to repress androgen receptor transcriptional activity in prostate cancer cell lines. Int. J. Mol. Med. 2011, 28:645-651. 10.3892/ijmm.2011.735.
82. Godoy A.S., Sotomayor P.C., Villagran M., Yacoub R., Montecinos V.P., McNerney E.M., et al. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression. Biochem. Biophys. Res. Commun. 2012, 423:564-570. 10.1016/j.bbrc.2012.06.005.
83. Mäki H.E., Saramäki O.R., Shatkina L., Martikainen P.M., Tammela T.L.J., van Weerden W.M., et al. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer. J. Pathol. 2007, 212:395-401. 10.1002/path.2186.
84. Jehle K., Cato L., Neeb A., Muhle-Goll C., Jung N., Smith E.W., et al. Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif. J. Biol. Chem. 2014, 289:8839-8851. 10.1074/jbc.M113.534859.
85. Khanna M., Qin K.N., Wang R.W., Cheng K.C. Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid dehydrogenases. J. Biol. Chem. 1995, 270:20162-20168.
86. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006, 66:2815-2825. 10.1158/0008-5472.CAN-05-4000.
87. Locke J.A., Guns E.S., Lubik A.A., Adomat H.H., Hendy S.C., Wood C.A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008, 68:6407-6415. 10.1158/0008-5472.CAN-07-5997.
88. Mostaghel E.A., Page S.T., Lin D.W., Fazli L., Coleman I.M., True L.D., et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007, 67:5033-5041. 10.1158/0008-5472.CAN-06-3332.
89. Liu C., Lou W., Zhu Y., Yang J.C., Nadiminty N., Gaikwad N.W., et al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res. 2015, 75:1413-1422. 10.1158/0008-5472.CAN-14-3080.
90. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648. 10.1126/science.1117679.
91. Powell K., Semaan L., Conley-LaComb M.K., Asangani I., Wu Y.-M., Ginsburg K.B., et al. ERG/AKR1C3/AR constitutes a feed-forward loop for AR signaling in prostate cancer cells. Clin. Cancer Res. 2015, 10.1158/1078-0432.CCR-14-2352.
92. Danila D.C., Anand A., Sung C.C., Heller G., Leversha M.A., Cao L., et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol. 2011, 60:897-904. 10.1016/j.eururo.2011.07.011.
93. Yin Y.D., Fu M., Brooke D.G., Heinrich D.M., Denny W.A., Jamieson S.M.F. The activity of SN33638, an inhibitor of AKR1C3, on testosterone and 17β-estradiol production and function in castration-resistant prostate cancer and ER-positive breast cancer. Front. Oncol. 2014, 4:159. 10.3389/fonc.2014.00159.
94. Chang K.-H., Li R., Kuri B., Lotan Y., Roehrborn C.G., Liu J., et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 2013, 154:1074-1084. 10.1016/j.cell.2013.07.029.
95. Uemura M., Tamura K., Chung S., Honma S., Okuyama A., Nakamura Y., et al. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 2008, 99:81-86. 10.1111/j.1349-7006.2007.00656.x.
96. Titus M.A., Gregory C.W., Ford O.H., Schell M.J., Maygarden S.J., Mohler J.L. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin. Cancer Res. 2005, 11:4365-4371. 10.1158/1078-0432.CCR-04-0738.
97. Uemura M., Honma S., Chung S., Takata R., Furihata M., Nishimura K., et al. 5αDH-DOC (5α-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. Cancer Sci. 2010, 101:1897-1904. 10.1111/j.1349-7006.2010.01620.x.
98. Chang K.-H., Li R., Papari-Zareei M., Watumull L., Zhao Y.D., Auchus R.J., et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:13728-13733. 10.1073/pnas.1107898108.
99. Fukami M., Homma K., Hasegawa T., Ogata T. Backdoor pathway for dihydrotestosterone biosynthesis: Implications for normal and abnormal human sex development. Dev. Dyn. 2013, 242:320-329. 10.1002/dvdy.23892.
100. Mostaghel E.A. Beyond T and DHT - Novel steroid derivatives capable of wild type androgen receptor activation. Int. J. Biol. Sci. 2014, 10:602-613. 10.7150/ijbs.8844.
101. Jernberg E., Thysell E., Bovinder Ylitalo E., Rudolfsson S., Crnalic S., Widmark A., et al. Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS ONE 2013, 8:e77407. 10.1371/journal.pone.0077407.
102. Hofland J., van Weerden W.M., Dits N.F.J., Steenbergen J., van Leenders G.J.L.H., Jenster G., et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 2010, 70:1256-1264. 10.1158/0008-5472.CAN-09-2092.
103. Auchus R.J., Yu M.K., Nguyen S., Mundle S.D. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 2014, 19:1231-1240. 10.1634/theoncologist.2014-0167.
104. Arora V.K., Schenkein E., Murali R., Subudhi S.K., Wongvipat J., Balbas M.D., et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013, 155:1309-1322. 10.1016/j.cell.2013.11.012.
105. Yemelyanov A., Bhalla P., Yang X., Ugolkov A., Iwadate K., Karseladze A., et al. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells. Cell Cycle 2012, 11:395-406. 10.4161/cc.11.2.18945.
106. Xie N., Cheng H., Lin D., Liu L., Yang O., Jia L., et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int. J. Cancer 2015, 136:E27-E38. 10.1002/ijc.29147.
107. Pan D., Kocherginsky M., Conzen S.D. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011, 71:6360-6370. 10.1158/0008-5472.CAN-11-0362.
108. Epstein J.I., Amin M.B., Beltran H., Lotan T.L., Mosquera J.-M., Reuter V.E., et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 2014, 38:756-767. 10.1097/PAS.0000000000000208.
109. Puccetti L., Supuran C.T., Fasolo P.P., Conti E., Sebastiani G., Lacquaniti S., et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur. Urol. 2005, 48:215-221. (discussion 221-223). 10.1016/j.eururo.2005.03.018.
110. Hirano D., Okada Y., Minei S., Takimoto Y., Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol. 2004, 45:586-592. 10.1016/j.eururo.2003.11.032.
111. Lipianskaya J., Cohen A., Chen C.J., Hsia E., Squires J., Li Z., et al. Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation. Asian J. Androl. 2014, 16:541-544. 10.4103/1008-682X.123669.
112. Yuan T.-C., Veeramani S., Lin F.-F., Kondrikou D., Zelivianski S., Igawa T., et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr. Relat. Cancer 2006, 13:151-167. 10.1677/erc.1.01043.
113. Kvissel A.-K., Ramberg H., Eide T., Svindland A., Skålhegg B.S., Taskén K.A. Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cell Signal. 2007, 19:401-409. 10.1016/j.cellsig.2006.07.011.
114. Jones S.E., Palmer T.M. Protein kinase A-mediated phosphorylation of RhoA on serine 188 triggers the rapid induction of a neuroendocrine-like phenotype in prostate cancer epithelial cells. Cell Signal. 2012, 24:1504-1514. 10.1016/j.cellsig.2012.03.018.
115. Rapa I., Volante M., Migliore C., Farsetti A., Berruti A., Vittorio Scagliotti G., et al. Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells. Prostate 2013, 73:1241-1249. 10.1002/pros.22679.
116. Zhang X.-Q., Kondrikov D., Yuan T.-C., Lin F.-F., Hansen J., Lin M.-F. Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 2003, 22:6704-6716. 10.1038/sj.onc.1206764.
117. Zhu Y., Liu C., Cui Y., Nadiminty N., Lou W., Gao A.C. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). Prostate 2014, 74:1086-1094. 10.1002/pros.22819.
118. Danza G., Di Serio C., Rosati F., Lonetto G., Sturli N., Kacer D., et al. Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol. Cancer Res. 2012, 10:230-238. 10.1158/1541-7786.MCR-11-0296.
119. Pernicová Z., Slabáková E., Fedr R., Šimečková Š., Jaroš J., Suchánková T., et al. The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells. Mol. Cancer 2014, 13:113. 10.1186/1476-4598-13-113.
120. Lin D., Wyatt A.W., Xue H., Wang Y., Dong X., Haegert A., et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014, 74:1272-1283. 10.1158/0008-5472.CAN-13-2921-T.
121. Palapattu G.S., Wu C., Silvers C.R., Martin H.B., Williams K., Salamone L., et al. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009, 69:787-798. 10.1002/pros.20928.
122. Kregel S., Kiriluk K.J., Rosen A.M., Cai Y., Reyes E.E., Otto K.B., et al. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS ONE 2013, 8:e53701. 10.1371/journal.pone.0053701.
123. Yu X., Cates J.M., Morrissey C., You C., Grabowska M.M., Zhang J., et al. SOX2 expression in the developing, adult, as well as, diseased prostate. Prostate Cancer Prostatic Dis. 2014, 17:301-309. 10.1038/pcan.2014.29.
124. Clermont P.-L., Lin D., Crea F., Wu R., Xue H., Wang Y., et al. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin. Epigenetics 2015, 7:40. 10.1186/s13148-015-0074-4.
125. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629. 10.1038/nature01075.
126. Beltran H., Rickman D.S., Park K., Chae S.S., Sboner A., MacDonald T.Y., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011, 1:487-495. 10.1158/2159-8290.CD-11-0130.
127. Sun Y., Wang B.-E., Leong K.G., Yue P., Li L., Jhunjhunwala S., et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Res. 2012, 72:527-536. 10.1158/0008-5472.CAN-11-3004.
128. Zhu M.-L., Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 2010, 24:769-777. 10.1096/fj.09-136994.
129. Cottard F., Asmane I., Erdmann E., Bergerat J.-P., Kurtz J.-E., Céraline J. Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells. PLoS ONE 2013, 8:e63466. 10.1371/journal.pone.0063466.
130. Kong D., Sethi S., Li Y., Chen W., Sakr W.A., Heath E., et al. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. Prostate 2015, 75:161-174. 10.1002/pros.22901.
131. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768. 10.1038/nrc2499.
132. Li F., Tiede B., Massagué J., Kang Y. Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res. 2007, 17:3-14. 10.1038/sj.cr.7310118.
133. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337. 10.1126/science.1142596.
134. Van Leenders G.J., Schalken J.A. Stem cell differentiation within the human prostate epithelium: Implications for prostate carcinogenesis. BJU Int. 2001, 88(Suppl 2):35-42. (discussion 49-50).
135. Nagle R.B., Ahmann F.R., McDaniel K.M., Paquin M.L., Clark V.A., Celniker A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res. 1987, 47:281-286.
136. De Marzo A.M., Meeker A.K., Epstein J.I., Coffey D.S. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am. J. Pathol. 1998, 153:911-919. 10.1016/S0002-9440(10)65632-5.
137. Stoyanova T., Cooper A.R., Drake J.M., Liu X., Armstrong A.J., Pienta K.J., et al. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:20111-20116. 10.1073/pnas.1320565110.
138. Grisanzio C., Signoretti S. p63 in prostate biology and pathology. J. Cell. Biochem. 2008, 103:1354-1368. 10.1002/jcb.21555.
139. Craft N., Chhor C., Tran C., Belldegrun A., DeKernion J., Witte O.N., et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999, 59:5030-5036.
140. Qin J., Liu X., Laffin B., Chen X., Choy G., Jeter C.R., et al. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012, 10:556-569. 10.1016/j.stem.2012.03.009.
141. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951. 10.1158/0008-5472.CAN-05-2018.
142. Rane J.K., Scaravilli M., Ylipaa A., Pellacani D., Mann V.M., Simms M.S., et al. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Eur. Urol. 2015, 67:7-10. 10.1016/j.eururo.2014.09.005.
143. Polson E.S., Lewis J.L., Celik H., Mann V.M., Stower M.J., Simms M.S., et al. Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nat. Commun. 2013, 4:1623. 10.1038/ncomms2627.
144. Kroon P., Berry P.A., Stower M.J., Rodrigues G., Mann V.M., Simms M., et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 2013, 73:5288-5298. 10.1158/0008-5472.CAN-13-0874.
145. Patrawala L., Calhoun T., Schneider-Broussard R., Li H., Bhatia B., Tang S., et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708. 10.1038/sj.onc.1209327.
146. Gu G., Yuan J., Wills M., Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 2007, 67:4807-4815. 10.1158/0008-5472.CAN-06-4608.
147. Rane J.K., Pellacani D., Maitland N.J. Advanced prostate cancer - A case for adjuvant differentiation therapy. Nat. Rev. Urol. 2012, 9:595-602. 10.1038/nrurol.2012.157.
148. Oldridge E.E., Pellacani D., Collins A.T., Maitland N.J. Prostate cancer stem cells: Are they androgen-responsive?. Mol. Cell. Endocrinol. 2012, 360:14-24. 10.1016/j.mce.2011.07.008.
149. Lang S.H., Anderson E., Fordham R., Collins A.T. Modeling the prostate stem cell niche: An evaluation of stem cell survival and expansion in vitro. Stem Cells Dev. 2010, 19:537-546. 10.1089/scd.2009.0291.
150. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760. 10.1038/nature05236.
151. Frame F.M., Pellacani D., Collins A.T., Simms M.S., Mann V.M., Jones G.D., et al. HDAC inhibitor confers radiosensitivity to prostate stem-like cells. Br. J. Cancer 2013, 109:3023-3033. 10.1038/bjc.2013.691.
152. Konopleva M., Zhao S., Hu W., Jiang S., Snell V., Weidner D., et al. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br. J. Haematol. 2002, 118:521-534.
153. Madjd Z., Mehrjerdi A.Z., Sharifi A.M., Molanaei S., Shahzadi S.Z., Asadi-Lari M. CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun. 2009, 9:4.
154. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67. 10.1186/1476-4598-5-67.
155. Santer F.R., Erb H.H., Oh S.J., Handle F., Feiersinger G.E., Luef B., et al. Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy. Oncotarget 2015, 6:6105-6122.
156. Shervington A., Lu C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest. 2008, 26:535-542. 10.1080/07357900801904140.
157. Brown M.D., Gilmore P.E., Hart C.A., Samuel J.D., Ramani V.A., George N.J., et al. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 2007, 67:1384-1396. 10.1002/pros.20620.
158. Drake J.M., Graham N.A., Lee J.K., Stoyanova T., Faltermeier C.M., Sud S., et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E4762-E4769. 10.1073/pnas.1319948110.
159. Aggarwal R.R., Ryan C.J., Chan J.M. Insulin-like growth factor pathway: A link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?. Urol. Oncol. 2013, 31:522-530. 10.1016/j.urolonc.2011.05.001.
160. Harle L.K., Maggio M., Shahani S., Braga-Basaria M., Basaria S. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin. Adv. Hematol. Oncol. 2006, 4:687-696.
161. Feilotter H.E., Nagai M.A., Boag A.H., Eng C., Mulligan L.M. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998, 16:1743-1748. 10.1038/sj.onc.1200205.
162. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4:209-221. 10.1016/S1535-6108(03)00215-0.
163. Mulholland D.J., Tran L.M., Li Y., Cai H., Morim A., Wang S., et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011, 19:792-804. 10.1016/j.ccr.2011.05.006.
164. Ferraldeschi R., Nava Rodrigues D., Riisnaes R., Miranda S., Figueiredo I., Rescigno P., et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur. Urol. 2015, 67:795-802. 10.1016/j.eururo.2014.10.027.
165. Jia S., Gao X., Lee S.H., Maira S.-M., Wu X., Stack E.C., et al. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 2013, 3:44-51. 10.1158/2159-8290.CD-12-0262.
166. Kolenko V., Teper E., Kutikov A., Uzzo R. Zinc and zinc transporters in prostate carcinogenesis. Nat. Rev. Urol. 2013, 10:219-226. 10.1038/nrurol.2013.43.
167. Smith D.J., Jaggi M., Zhang W., Galich A., Du C., Sterrett S.P., et al. Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Urology 2006, 67:1341-1347. 10.1016/j.urology.2005.12.032.
168. Yamasaki M., Mimata H., Nomura T., Sato F. Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol. Rep. 2007, 10.3892/or.18.5.1145.
169. Sato M., Bremner I. Oxygen free radicals and metallothionein. Free Radical Biol. Med. 1993, 14:325-337. 10.1016/0891-5849(93)90029-T.
170. Otsuka T., Hamada A., Iguchi K., Usui S., Hirano K. Suppression of metallothionein 3 gene expression by androgen in LNCaP prostate cancer cells. Biomed. Rep. 2013, 1:614-618. 10.3892/br.2013.107.
171. Cherian M.G., Apostolova M.D. Nuclear localization of metallothionein during cell proliferation and differentiation. Cell. Mol. Biol. (Noisy-Le-Grand) 2000, 46:347-356.
172. Abdel-Mageed A., Agrawal K.C. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther. 1997, 4:199-207.
173. Notta F., Koropatnick D.J. Metallothioneins in drug resistance. Cancer Drug Resistance 2006, 223-239. Humana Press, Totowa, NJ. B.A. Teicher (Ed.).
174. Mercader M., Bodner B.K., Moser M.T., Kwon P.S., Park E.S.Y., Manecke R.G., et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. PNAS 2001, 98:14565-14570. 10.1073/pnas.251140998.
175. Drachenberg D.E., Elgamal A.A., Rowbotham R., Peterson M., Murphy G.P. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999, 41:127-133.
176. Cavarretta I.T., Neuwirt H., Zaki M.H., Steiner H., Hobisch A., Nemeth J.A., et al. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Hormonal Carcinogenesis V 2008, 547-555. Springer, New York. J.J. Li, S.A. Li, S.M.H.R.,.M.T.M. Mohla (Eds.).
177. Fizazi K., Faivre L., Lesaunier F., Delva R., Gravis G., Rolland F., et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial. Lancet Oncol. 2015, 10.1016/S1470-2045(15)00011-X.